Clinical trial ongoing.

It is estimated that approximately 3.7 million patients in the US currently suffer from chronic wounds, which include pressure ulcers, diabetic foot ulcers and venous leg ulcers. These wounds are particularly difficult to heal, impair the patient’s quality of life and can lead to serious complications, such as amputations.

The care of such chronic wounds is estimated to be over $1 billion dollars a year in the US. Current treatments include advanced wound dressings, growth factor gels or bioengineered tissue products.

BST-DermOn™ is a topical therapy, which conforms well to the wound and may help stimulate the natural healing process. It may maintain the wound’s moist environment while allowing gas exchange. The wound healing, as well as inherent hemostatic and bacterio-static properties of the chitosan component of BST-DermOn™ has well-documented in the scientific literature. Our animal studies have shown that it stimulates and supports the intrinsic healing process of slow or non-healing wounds

An open pilot study was recently completed. Positive results were summarized in a poster presentation at the 3ed congress of the World Union of Wound Healing Societies (WUWHS) held in Toronto on June 4-8, 2008.

To view poster please click WUWHS 2008